Cell Specific Dopamine Modulation of the Transient Potassium Current in the Pyloric Network by the Canonical D1 Receptor Signal Transduction Cascade

Hongmei Zhang, Edmund W. Rodgers, Wulf-Dieter C. Krenz, Merry C. Clark, and Deborah J. Baro

Department of Biology, Georgia State University, Atlanta, Georgia

Submitted 19 February 2010; accepted in final form 28 May 2010

Zhang H, Rodgers EW, Krenz WD, Clark MC, Baro DJ. Cell specific dopamine modulation of the transient potassium current in the pyloric network by the canonical D1 receptor signal transduction cascade. J Neurophysiol 104: 873–884, 2010. First published June 2, 2010; doi:10.1152/jn.00195.2010. Dopamine (DA) modifies the motor pattern generated by the pyloric network in the stomatogastric ganglion (STG) of the spiny lobster, Panulirus interruptus, by directly acting on each of the circuit neurons. The 14 pyloric neurons fall into six cell types, and DA actions are cell type specific. The transient potassium current mediated by shal channels ($I_{\text{A}}$) is a common target of DA modulation in most cell types. DA shifts the voltage dependence of $I_{\text{A}}$ in opposing directions in pyloric dilator (PD) versus lateral pyloric (LP) neurons. The mechanism(s) underpinning cell type specific dopamine modulation of $I_{\text{A}}$ is unknown. DA receptors (DARs) can be classified as type 1 (D1R) or type 2 (D2R). D1Rs and D2Rs are known to increase and decrease intracellular cAMP concentrations, respectively. We hypothesized that the opposing DA effects on PD and LP $I_{\text{A}}$ were due to differences in DAR expression patterns. In the present study, we found that LP expressed somatodendritic D1Rs that were concentrated near synapses but did not express D2Rs. Consistently, DA modulation of LP $I_{\text{A}}$ was mediated by a Gs-adenyl cyclase-cAMP-protein kinase A pathway. Additionally, we defined antagonists for lobster D1Rs (flupenthixol) and D2Rs (metoclopramide) in a heterologous expression system and showed that DA modulation of LP $I_{\text{A}}$ was blocked by flupenthixol but not by metoclopramide. We previously showed that PD neurons express D2Rs, but not D1Rs, thus supporting the idea that cell specific effects of DA on $I_{\text{A}}$ are due to differences in receptor expression.

INTRODUCTION

The crustacean pyloric network is a powerful model for studying neuromodulation of rhythmic behaviors. All the major cells and their circuit connections are known. Many projection and sensory neurons that modulate the network have been defined (Blitz et al. 2008; Daur et al. 2009; DeLong et al. 2009; Hedrich et al. 2009; Stein et al. 2007), and the modulatory effects of monoamines and peptides on this circuit have been extensively studied (Marder and Bucher 2007; Nusbaum and Beenakker 2002; Stein 2009).

Pyloric neurons receive both neuromodulatory and -hormonal dopamine (DA) transmissions. A few DA-containing neurons in the two commissural ganglia (COGs) project to the stomatogastric ganglion (STG) via the superior esophageal nerve (Goldstone and Cooke 1971; Kushner and Barker 1983; Kushner and Maynard 1977; Pulver et al. 2003; Sullivan et al. 1977; Tierney et al. 2003) and release DA to pyloric neurons largely in a paracrine fashion (Oginsky et al. 2010). Additionally, the STG resides in a major blood vessel, and the L-cells located in the COGs project to the cardiac ganglion and release neurohormonal DA into the hemolymph (Pulver and Marder 2002; Tierney et al. 2003).

Bath applied DA alters circuit output by differentially modulating pyloric neuron synaptic and intrinsic firing properties (Harris-Warrick et al. 1998). This is partially mediated by DA modulation of several ion channels (Cleland and Selverston 1997; Harris-Warrick et al. 1995a,b, 1998; Johnson et al. 2003a; Kloppenburg et al. 1999, 2000; Peck et al. 2001, 2006). Here we focus on DA modulation of $I_{\text{A}}$, which helps determine the rate of postinhibitory rebound and spike frequency in pyloric neurons and influences pyloric cycle frequency and phase constancy (Ayali and Harris-Warrick 1998, 1999; Golowasch et al. 1992; Harris-Warrick et al. 1995a,b; Hooper 1997; Johnson et al. 2005; Tierney and Harris-Warrick 1992).

DA targets $I_{\text{A}}$ to differentially alter pyloric neuron activity. For example, in pyloric dilator (PD) neurons bath-applied DA increases $I_{\text{A}}$ maximal conductance and shifts the voltage dependence for activation to more hyperpolarized potentials without altering the voltage dependence for inactivation (Kloppenburg et al. 1999). As a result, the transient (peak) current is increased at all depolarizing membrane potentials where $I_{\text{A}}$ is activated. Further, the window current between the activation and inactivation curves is enlarged, and this increase in the tonic (sustained or steady-state) $I_{\text{A}}$ causes the PD neuron to hyperpolarize. On the other hand, bath applied DA modulates the lateral pyloric (LP) $I_{\text{A}}$ by reducing its maximal conductance and shifting the voltage dependence of both activation and inactivation in the depolarizing direction (Harris-Warrick et al. 1995b). This reduces the transient $I_{\text{A}}$ at all depolarizing potentials and shifts the window current so that the maximal tonic $I_{\text{A}}$ occurs at more depolarized potentials. Ultimately this differential modulation of $I_{\text{A}}$ in PD versus LP neurons contributes to a decrease versus increase in action potential firing and a phase delay versus advancement of neuronal activity, respectively.

The mechanism(s) underpinning this opposing DA modulation of PD and LP $I_{\text{A}}$ is unknown. There are no obvious differences in the ion channels mediating PD and LP $I_{\text{A}}$. Shal channels mediate $I_{\text{A}}$ and appear to have the same subcellular distribution in both identified cell types such that they are found throughout the somatodendritic compartment and in axon terminals (Baro et al. 1996, 1997, 2000). We therefore hypothesized that differences in DA transduction cascades may underpin the opposing effects of DA on each cell type.

DA acts on several highly conserved DARs that belong to the G-protein-coupled receptor (GPCR) superfamily. In the traditional view, a given type of GPCR signals through one of four classes of G proteins: Gs, Gi/o, Gq/11, and G12/13.

Address for reprint requests and other correspondence: D. J. Baro, Dept. of Biology, Georgia State University, P.O. Box 4010, Atlanta GA 30302-4010 (E-mail: dbaro@gsu.edu).
(Cabrera-Vera et al. 2003). All DARs can be classified into two types based on their G protein coupling: D1Rs and D2Rs (Neve et al. 2004). In the canonical pathways, D1Rs couple with Gs to increase adenylyl cyclase (AC) activity and D2Rs couple with Gai/o to decrease AC activity, thereby increasing and decreasing cAMP levels, respectively. The change in cAMP concentration will then alter protein kinase A (PKA) activity, which in turn will alter the phosphorylation state of a number of substrates. The two spiny lobster D1Rs, D1\textsubscript{LaPan} and D1\textsubscript{lbPan}, and the single D2R, D2\textsubscript{Pan}, signal through canonical G-protein-coupled pathways when overexpressed in human embryonic kidney cells (HEK) cells (Clark and Baro 2006, 2007) and in native stomatogastric membrane preparations (Clark et al. 2008). In addition to canonical G-protein-coupled signaling, GPCRs have recently been found to signal through noncanonical pathways that may or may not involve G proteins. We have shown that both types of lobster DARs can signal through evolutionarily conserved, noncanonical pathways. In STG membrane preparations, D1\textsubscript{LaPan} can couple with Gq to activate phospholipase C\beta (PLC\beta) as well as Gs (Clark et al. 2008). It is not clear whether both types of coupling occur in a single neuron and/or whether the distinct cascades alter the same targets. D2\textsubscript{Pan} can couple with PLC\beta via G\beta\gamma, when expressed in HEK cells (Clark and Baro 2007). We have recently shown that PD neurons express D2Rs but not D1Rs (Oginsky et al. 2010). PD DARs are concentrated in perisynaptic regions in the somatodendritic but not axonal compartments. In the present study, we test the hypothesis that DA has opposing effects on PD and LP \( \lambda \) because LP neurons express D1Rs while PD neurons express D2Rs.

**METHODS**

**Drugs**

Drugs were all purchased from Sigma (St. Louis, MO) except Rp-cAMP, tetrodotoxin (TTX), and H-89 (Tocris Bioscience, Bristol, UK). The strategy we used to choose drugs that would block the actions of AC and PKA is as follows: the sites of action for H-89 and Rp cAMP on PKA, and forskolin on AC, were determined from the literature. Using Megalign (DNASTAR), we then aligned these sites in homologues from mammals and invertebrates, including crustaceans. In addition we performed Blast searches with these regions. In homologues from mammals and invertebrates, including crustaceans. In addition we performed Blast searches with these regions.

**Animals**

California spiny lobsters, *Panulirus interruptus*, were purchased from Don Tomlinson Commercial Fishing (San Diego, CA) and kept in aerated and filtered artificial saltwater.

**Dissection and cell identification**

Lobsters were cold-anesthetized for 30 min and the stomatogastric nervous system (STNS) was dissected as previously described (Bierman and Tobin 2009; Tobin and Bierman 2009). The STNS was pinned in a silicone elastomer (Sylgard)-lined dish and continuously superfused with *Panulirus* (P.) saline, which contained (in mM) 479 NaCl, 12.8 KCl, 13.7 CaCl\(_2\), 39 Na\(_2\)SO\(_4\), 10 MgSO\(_4\), 2 glucose, 4.99 HEPES, and 5 TES; pH 7.4. Cells were identified using standard intra- and extracellular recording techniques as previously described (Harris-Warrick et al. 1995a,b). Neuronal activity was monitored with intracellular somatic recordings using 20–40 M\(\)Ω glass microelectrodes filled with 3 M KCl and Axoclamp 2B or 900A amplifiers (Axon Instruments, Foster City, CA). Extracellular recordings of identified motoneurons were obtained using a differential AC amplifier (A-M Systems, Everett, WA) and stainless steel pin electrodes. Neurons were identified by their distinct waveforms, the timing of their voltage oscillations, and correlation of spikes on the extracellular and intracellular recordings.

**Immunohistochemistry (IHC)**

The identified LP neuron was filled with a lysine fixable, dextran coupled Texas Red fluorophore that was impermeable to gap junctions (MW 10,000; Molecular Probes), as previously described (Clark et al. 2008). A 1% solution of the fluorophore in 0.2 mol/l KCl was pressure injected (8–20 psi, 200 ms pulse, 0.05 Hz) using an 8–15 M\(\) glass microelectrode and a PicoSpritzerIII (General Valve/Parker Hannifin). The fluorophore was injected until the cell became dark purple (typically 15–25 min, depending on the microelectrodes resistance), and the preparation was incubated for 4–24 h at room temperature to allow the fluorophore to diffuse. The preparation was then fixed and DAR protein distributions were determined using whole mount STG preparations in IHC experiments, followed by confocal microscopy. The IHC protocol was as previously described (Baro et al. 2000; Clark et al. 2004). The primary, affinity purified antibodies against the three lobster DARs (D1\textsubscript{LaPan}, D1\textsubscript{lbPan}, and D2\textsubscript{Pan}) and their respective specificities were previously described (Clark et al. 2008; Oginsky et al. 2010). Data were acquired with a LSM510 confocal laser scanning microscope from Carl Zeiss Microimaging (Oberkochen, Germany).

**cAMP assays in a heterologous expression system**

Receptors were transiently expressed in HEK as previously described (Spitzer et al. 2008a). Cells that overexpressed a given receptor were exposed to DA or DA plus varying concentrations of a given antagonist. The change in cAMP levels induced by DA or DA plus antagonist were measured using an ELISA assay kit (Assay Designs) as previously described (Clark and Baro 2006, 2007; Spitzer et al. 2008a,b). Data were analyzed with Prism (Graph-Pad) and Excel (Microsoft) software.

**TEVC**

For two electrode voltage clamp (TEVC), the desheathed stomatogastric nerve (\( \text{sn} \)) and STG were isolated in separate petroleum jelly (Vaseline) wells. The STG was superfused continuously at room temperature with *Panulirus* saline using a Rainin Dynamax peristaltic pump (Rainin). For all experiments, temperature was continuously monitored with a miniature probe in the bath. After cell identification, descending inputs were removed with a sucrose block applied into the well surrounding the \( \text{sn} \) for 1 h. Glutamatergic synaptic inputs were blocked with picrotoxin (10 M). The known voltage-dependent ion channels except \( \text{I}_\text{x} \) were blocked with bath-applied TTX (10\textsuperscript{−7} M, \( \text{I}_{\text{K(Ca)}} \)), TEA (2 \times 10\textsuperscript{−7} M, \( \text{I}_{\text{K(V)}} \) and \( \text{I}_{\text{K(Ca)}} \)), CsCl (5 \times 10\textsuperscript{−3} M, \( \text{I}_{\text{Cs}} \)) and CdCl\(_2\) (2 \times 10\textsuperscript{−4} M, \( \text{I}_{\text{Cd}} \)). 

\( \text{I}_\text{x} \) was analyzed as previously described (Baro et al. 1997) using Axoclamp 2B and 900A amplifiers and Clampex 8.2 and 10.2 software (Axon Instruments). The LP neuron was impaled with low resistance (5–9 MΩ) microelectrodes filled with 3 M KCl. Cells were held at −50 mV holding potential between experimental protocols. The voltage dependence of activation was measured by a series of sweeps in which a hyperpolarizing prepulse to −90 mV for 200 ms was followed by a 500 ms depolarizing test pulse that ranged from −50 to +60 mV with 10 mV increments. Steady-state inactivation was measured with a series of sweeps in which the membrane potential was stepped to a prepulse between −110 and −20 mV with
10 mV increments (200 ms) followed by a constant test pulse to +20 mV (500 ms). Besides the pharmacological isolation described in the preceding text, \( I_A \) was further isolated by digital subtraction of the leak conductance. For activation, \( I_A \) was evoked by test pulses between −50 and +60 mV from −50 mV holding potential without a negative prepulse. This leaves a relatively linear leak current, which, however, contains a transient component of \( I_A \) that is not inactivated at −50 mV. Typically this does not exceed 10% of the peak conductance and was therefore tolerated. These current traces were subtracted from those evoked with negative prepulse. For inactivation, the subtraction protocol contained a depolarizing prepulse to −20 mV before the test pulse to +20 mV.

Data were analyzed with Clampfit v.8.2 and 10.2 (Axon Instruments), Prism v.4 and 5 (Graphpad) and Excel (Microsoft). After digital subtraction, peak currents measured at each voltage step were converted into conductance using the formula \( G = I_{\text{peak}}/(V - E_K) \), assuming \( E_K = −86 \) mV (Eisen and Marder 1982). The calculated conductance and the corresponding voltage were then used to construct conductance-voltage plots. Plots were fit with a first-order Boltzmann equation to obtain the maximal conductance (\( G_{\text{max}} \)), the apparent voltage of half activation (\( V_{1/2(\text{activation})} \)), and voltage of half inactivation (\( V_{1/2(\text{inactivation})} \)).

Many biophysical channel properties are temperature dependent. In preliminary studies, we performed experiments either at room temperature (which did not vary during an experiment and never varied by >3°C across experiments, from 19 to 22°C) or at 16°C (maintained by placing the perfusion tubing in an ice water bath). The results of these studies showed that the DA induced shifts in \( I_A \) voltage dependencies were not temperature sensitive. Average shifts were almost exactly the same and not significantly different when measured at room temperature or at 16°C. Therefore for convenience, experiments were performed at room temperature, and all data included in this manuscript were obtained at room temperature.

**Drug application**

In most experiments, drugs were continuously superfused into the STG well. However, to save on costs, during Rp-cAMP application, perfusion pumps were stopped after the drug was applied to the bath and the bath volume had been replaced at least five times. Pumps were started again for washout. No changes in holding currents or temperature were observed during this process. In all experiments, the concentration of DA was −10−5M, except the Rp-cAMP experiments. To save on costs, DA was reduced to 5 × 10−6 M so that less blocker was required. In some experiments (\( n ≥ 1 \)), the order of application was reversed to show that the drug had the same effect regardless of whether or not it was preceded by DA application (e.g., antagonist alone and antagonist +DA applications were before the DA application). We also confirmed that serial applications of DA separated by a 30 min wash had the same effects on LP \( I_A \) (i.e., no significant differences in the DA induced shifts produced by DA application 1 vs. 2).

**Statistical analyses**

Unless otherwise indicated, data are shown as means ± SE. Student’s t-test were performed with Excel software. One-way (repeated measures) ANOVA was performed with GraphPad Prism software, Tukey’s post hoc tests were performed where appropriate. Statistical significance was determined as \( P < 0.05 \).

**RESULTS**

**D1Rs, but not D2Rs, are expressed in LP neurons**

To understand how DA modulates LP \( I_A \), we first defined LP DAR expression. We performed IHC experiments on STG whole mount preparations, each containing a dye-filled LP neuron. Three custom made, affinity purified antibodies, each specific for one of the three lobster DARs, were used in conjunction with confocal microscopy as previously described (Clark et al. 2008; Oginsky et al. 2010). Overlapping 1 μm confocal optical sections throughout the somatodendritic compartment of a given LP neuron were examined for the presence of a given receptor. The data suggested that receptor expression in the somatodendritic compartment was consistent across preparations: \( D_{1\alpha}\text{Pan} \) and \( D_{1\beta}\text{Pan} \) receptors were always observed in LP neurons, but \( D_{2\alpha}\text{Pan} \) receptors were never detected (\( n = 5 \) for each DAR; Fig. 1).

Similar to our findings for PD D2Rs (Clark et al. 2008; Oginsky et al. 2010), LP D1Rs appeared to be located in somatodendritic endomembrane structures (Fig. 1, A, B, and F). D1Rs were also detected in primary and higher order neurites (Fig. 1, C, D, and G). Careful examination of the optical sections showed that receptors were not associated with the plasma membrane in these structures but in endomembrane compartments. Receptors were most highly concentrated in varicosities along, or at the terminals of fine neurites (Fig. 1, C, E, H, and I), which are known to represent synaptic structures (King 1976a,b). \( D_{1\alpha}\text{Pan} \) and \( D_{1\beta}\text{Pan} \) receptors often appeared to be in the plasma membrane of synaptic varicosities, as there was no rim of red cytoplasm surrounding receptor immunoreactivity (Fig. 1, E and I).

Our previous studies suggested that D1Rs may be expressed in glial cells (Oginsky et al. 2010). Figure 1, A and C, illustrates that \( D_{1\beta}\text{Pan} \) receptors were highly expressed in the processes of glial and/or other support cells in the STG. It was not clear from our IHC experiments whether or not \( D_{1\alpha}\text{Pan} \) and \( D_{2\alpha}\text{Pan} \) receptors were also expressed in glial cells. They are not obviously in the membrane of glial somata as are shal channels (Baro et al. 2000). If these DARs are expressed in glia, they have a punctate distribution and cannot be differentiated from neuronal staining.

**LP D1Rs couple with \( I_A \) through a Gs-AC-PKA, but not Gq, cascade**

We previously showed that \( D_{1\alpha}\text{Pan} \) and \( D_{1\beta}\text{Pan} \) couple with Gs, and \( D_{1\alpha}\text{Pan} \) can also couple with Gq in STNS membrane preparations (Clark et al. 2008). If DA acts exclusively through D1Rs, then DA effects on LP \( I_A \) may be mediated by Gs and/or Gq transduction cascades. A pharmacological dissection of the DA induced transduction cascades modulating LP \( I_A \) was therefore performed using TEVC.

Consistent with previous reports (Harris-Warrick et al. 1995b), a 10 min bath application of 10−3 M DA decreased the LP \( I_A \) evoked by a depolarizing test pulse following a hyperpolarizing prepulse to remove all channel inactivation (Fig. 2A). First order Boltzmann fits of the conductance voltage relations for activation and inactivation suggested that this decrease was largely the result of reversible DA induced shifts in \( I_A \) voltage dependencies to more positive potentials (Fig. 2B). Regardless of their initial voltage dependencies, most cells showed similar depolarizing shifts in their apparent voltages of half activation (Fig. 2C) and inactivation (D). The average shifts were statistically significant for both activation (3.4 ± 0.3 mV, \( n = 41 \), paired t-test, \( P < 0.0001 \)) and inactivation (3.9 ± 0.3 mV, \( n = 33 \), paired t-test, \( P < 0.0001 \)). It is noteworthy that <10% of the cells examined...
did not respond to DA or responded with a smaller negative shift; however, these data were not excluded from the analyses. As previously reported (Harris-Warrick et al. 1995b), we also observed that DA produced a significant decrease the I_A maximal conductance (Fig. 2A), but this effect was not reversible and therefore not considered in this study.

We first tested whether DA shifted the voltage dependence of LP I_A via a Gs cascade. AC converts ATP to cAMP, and Gs can stimulate AC activity. Forskolin directly activates AC in all species by binding to the conserved catalytic core (Yan et al. 1997, 1998; Zhang et al. 1997) (see also METHODS), and this drug has been successfully used to activate AC in several
invertebrates including *Drosophila* and crustaceans (Kim and Wu 1996; Klein 1993; Nakatsuji et al. 2009). We asked whether or not forskolin could mimic, and at saturating concentrations occlude, the effects of DA on LP $I_A$ (Fig. 3). A 10 min 10^{-5} M DA application was followed by a 30 min washout, and forskolin (5 $\times$ 10^{-5} M) was applied for 10 min followed by a 10 min application of DA (10^{-5} M) plus forskolin (5 $\times$ 10^{-5} M). LP $I_A$ was recorded at the end of each drug application and wash. Forskolin alone produced depolarizing shifts in the LP $I_A$ $V_{1/2}$ activation (Fig. 3A, 6.2 ± 0.8 mV, n = 5) and $V_{1/2}$ inactivation (Fig. 3B, 3.8 ± 0.7 mV, n = 5). These shifts were significantly different from control (ANOVA, P < 0.01), but not from the shift induced by DA alone. Thus forskolin mimicked the effects of DA on LP $I_A$. Moreover, addition of 10^{-5} M DA to preparations that previously received 5 $\times$ 10^{-5} M forskolin did not produce further significant shifts in the voltage dependence (ANOVA, P > 0.05). Thus saturating levels of forskolin can occlude the effects of DA on LP $I_A$. To exclude the possibility that forskolin acted directly on shal channels, rather than on AC, we

![Fig. 2](http://jn.physiology.org/)

**FIG. 2.** DA induced positive shifts in the voltage dependence of LP $I_A$. A: TEVC recordings under control conditions, with 10 min bath application of 10^{-5} M DA and after 30 min washout of DA. Current traces were obtained in response to a series of depolarizing test pulses (from −50 to +60 mV in 10 mV increments) following a hyperpolarizing prepulse to −90 mV. All voltage dependent ion channels except $I_A$ were pharmacologically blocked. Scale bars represent 100 ms and 50 nA. B: normalized conductance–voltage plots for activation (□, ■, ▲) and inactivation (▲, ■, ▲) fit with a 1st-order Boltzmann equation. Plots were obtained under control condition (□, ■), with 10 min 10^{-5} M DA application (▲, ■), and after 30 min washout of DA (▲, ▲). n = 5 for each data point. C and D: preparation-to-preparation variability. ▲, the $I_A$ $V_{1/2}$ activation (C) and inactivation (D) for a single individual in the presence (y axis) versus absence (x axis) of 10^{-5} M DA. The line indicates unity and points above and below the line indicate that DA shifted the $V_{1/2}$ to more depolarized or hyperpolarized potentials, respectively.

![Fig. 3](http://jn.physiology.org/)

**FIG. 3.** An adenylyl cyclase (AC) activator mimicked and, at saturating concentrations, largely occluded the effects of DA on LP $I_A$. $I_A$ was recorded before (baseline) and 10 min after application of 10^{-5} M DA, 5 $\times$ 10^{-5} M forskolin, DA+forskolin, or 5 $\times$ 10^{-5} M dideoxy-forskolin (dd-forskolin). Every preparation received only 1 of the 4 drug treatments. Each drug except dd-forskolin induced a significant and reversible shift in LP $I_A$ $V_{1/2}$ activation (A) and inactivation (B) relative to baseline. *, significant difference from baseline using 1 way ANOVAs with a Tukey post hoc test.

*J. Neurophysiol.* Vol 104 • August 2010 • www.jn.org
examined the effect of 1,9-dideoxyforskolin (dd-forskolin), a structural analogue of forskolin that does not activate AC. We found that dd-forskolin had no significant effects on LP $I_A$ ($n = 3$). Taken together, these data suggest that DA shifts the voltage dependence of $I_A$ at least partially through AC.

DA produced dose-dependent shifts in the LP $I_A$ $V_{1/2}$ activation (Fig. 4A). If DA signals largely through the Gs cascade, then increasing doses of DA should result in increasing concentrations of cAMP. We therefore asked whether or not cAMP could mediate DA’s actions. We found that, like DA, bath applying varying concentrations of the membrane permeable cAMP analogue, 8-bromo-cAMP, and measuring the $V_{1/2}$ activation. Note that cAMP is a small second messenger molecule that is not encoded by the genome and that does not vary across species; thus 8-bromo-cAMP will be effective in crustaceans. We found that, like DA, cAMP produced dose-dependent positive shifts in the $V_{1/2}$ activation (Fig. 4B). Moreover, similar to the effect of bath applied DA, an increase in the cAMP concentration could also shift the $V_{1/2}$ inactivation to more depolarized membrane potentials (Fig. 4, ●).

PKA is one of the major effectors of cAMP. To test whether PKA was involved in the signaling pathway mediating DA’s effect on LP $I_A$, we examined whether or not the PKA inhibitor, H-89, could block DA’s actions. H-89, which has been successfully used in crustaceans (Philipp et al. 2006), inhibits PKA by targeting the ATP binding site (Chijiwa et al. 1990; Engh et al. 1996), which is conserved across species (Gross et al. 1990) (see also METHODS). In these experiments, the preparation was exposed to $10^{-5}$ M DA for 10 min, followed by a 30 min wash. H-89 (2 × $10^{-5}$M), was then applied for 10 min followed by an application of H-89 plus DA. $I_A$ was recorded prior to DA application, at the end of each drug treatment, and after the 30 min wash. The voltages of half activation and inactivation were determined for each condition, and the change from baseline was plotted in Fig. 5, where baseline is the $V_{1/2}$ prior to drug treatment (DA) or after the wash (H-89, H-89 + DA). The data demonstrated that H-89 reversibly inhibited the DA induced shift in $V_{1/2}$ activation (ANOVA, $P < 0.001, n = 5$, Fig. 5A) and inactivation (ANOVA, $P < 0.001, n = 5$, B). Because H-89 can also inhibit other kinases, such as PKG, we repeated the experiment with a specific and expensive PKA inhibitor, Rp-cAMP. This drug occupies the cAMP binding site on the regulatory subunit of PKA, thus preventing the holoenzyme from dissociating (Rothermel and Parker Botelho 1988). The cAMP binding site on the regulatory subunit is well conserved across species (Canaves and Taylor 2002) (see also METHODS), and this drug has been used successfully in several arthropods including Drosophila and crustaceans (Erxlben et al. 1995; Kuromi and Kidokoro 2000). To save on the cost of the inhibitor in this experiment, the concentration of DA was reduced to 5 µM. Whereas 5 µM DA induced a significant and reversible shift in $I_A$ $V_{1/2}$ activation...
ANOVA, $P < 0.001$, $n = 4$, Fig. 5C) and inactivation (ANOVA, $P < 0.01$, $n = 4$, Fig. 5D). Rp-cAMP blocked this effect. Interestingly, Rp-cAMP itself significantly altered $I_A V_{1/2}$ inactivation (ANOVA, $P < 0.05$, $n = 4$, Fig. 5D). This might suggest that PKA constitutively modulates the $I_A V_{1/2}$ inactivation. Indeed, both PKA blockers, H-89 and Rp-cAMP, shifted $I_A$ voltage dependencies in the opposite direction to DA, but in most cases the changes were not statistically significant. Taken together, our data suggest that the Gas-AC-cAMP-PKA signaling pathway mediates DA modulation of $I_A$ in the LP neuron, consistent with the fact that LP expresses somatodendritic D1Rs but not D2Rs.

As mentioned in the preceding text, D$_{1\alpha}$Pan receptors also couple with Gq in STNS membrane preparations. PLC$\beta$ is the major downstream effector of activated Gq subunits. The ether lipid analogue ET-18-OCH$_3$ is a known PLC$\beta$ inhibitor (Powis et al. 1992). ET-18-OCH$_3$ exerts its effects by being incorporated into the plasma membranes of cells (Aroca et al. 2001; Heczkova and Slotte 2006; Powis et al. 1992), but how ET-18-OCH$_3$ inhibits PLC$\beta$ is not clear to date. Nevertheless, ET-18-OCH$_3$, has been successfully used in invertebrate neurons to inhibit PLC$\beta$ (Wong et al. 2007). Using the aforementioned experimental paradigm, we asked whether DA modulation of $I_A$ could be blocked by addition of ET-18-OCH$_3$. Figure 6 illustrates that ET-18-OCH$_3$ did not prevent the DA induced positive shift in $I_A$ voltage dependencies, suggesting that DA does not modulates LP $I_A$ through a Gq cascade.

**DAR specific antagonists confirm that DA acts on LP $I_A$ through D1Rs**

To further confirm that DA modulates LP $I_A$ exclusively through D1Rs, we sought to obtain antagonists specific for lobster D1Rs and D2Rs. It is well established that monoamine receptor pharmacology is not well conserved between vertebrate and invertebrate receptors (Blenau and Baumann 2001; Spitzer et al. 2008a,b; Tierney 2001) because many agonists and antagonists do not bind to evolutionarily conserved amino acids. This is in contrast to the blockers of the transduction cascades that we used (i.e., forskolin, H-89, Rp-cAMP, ET-18-OCH$_3$), which act at functional domains that are evolutionarily conserved. We therefore performed a preliminary screen using a cadre of drugs (Table 1) and found candidate antagonists for lobster D1Rs (flupenthixol) and D2Rs (metoclopramide). The effects of these drugs were characterized in detail using a transient, heterologous expression system and assays for DA induced changes in cAMP concentration in the presence and absence of flupenthixol and metoclopramide. Figure 7 illustrates that, consistent with previous studies (Clark and Baro 2006, 2007), DA altered cAMP levels in both D1R and D2R expressing HEK cells. Flupenthixol, but not metoclopramide, blocked the DA induced increase in cAMP in HEK cells expressing D$_{1\alpha}$Pan receptors (Fig. 7A, $n \geq 3$) and D$_{1\beta}$Pan receptors (B, $n \geq 3$). On the other hand, Fig. 7C shows that the DA induced changes in cAMP were prevented by metoclopramide in D$_{2\alpha}$Pan expressing HEK cells ($n = 3$). If DA acts on LP neurons exclusively through D1Rs, then flupenthixol should block DA modulation of HEK cells whereas metoclopramide should not. Figure 8 illustrates that this is indeed the case. Using TEVC, we measured the DA induced change in the $V_{1/2}$ activation and $V_{1/2}$ inactivation in LP in the presence and absence of each antagonist. In these experiments, DA ($10^{-5}$ M) was bath applied for 10 min and washed for 30 min; then, $10^{-5}$ M antagonist was bath applied for 5 min, followed by a 10 min application of antagonist plus DA followed by a 30 min wash. $I_A V_{1/2}$ was measured at the end of each drug application and the wash period. In some cases ($n = 1$ for each antagonist), the application order was altered as described in METHODS. We found that $10^{-5}$ M flupenthixol reversibly blocked the DA induced shift in $I_A$ activation from 3.18 $\pm$ 0.38 mV ($n = 10$) to 0.27 $\pm$ 0.75 mV ($n = 5$) and inactivation from 3.95 $\pm$ 0.49 mV ($n = 10$) to 0.81 $\pm$ 1.3 mV ($n = 5$). The shifts induced by DA were significantly different from those induced by DA+ flupenthixol (ANOVA, $P < 0.01$). On the other hand, metoclopramide had no significant effect on the DA induced changes in LP $I_A$. Taken together, the data indicate that DA modulates LP $I_A$ exclusively through D1Rs.

**DISCUSSION**

DA is known to modulate intrinsic neuronal firing properties and synaptic strengths in a number of systems by acting on a
demonstrated that LP D1Rs modulated ionicy blocked by D1R but not D2R antagonists. Further, we increased calcium currents (Peck et al. 2006). DA increases excitability and phase advances PD (Flamm and Harris-Warrick 1986a,b; Harris-Warrick et al. 1998) or a downstream enzyme (e.g., phosphatase) that then modifies shal subunits. Three criteria were used to select an antagonist: ability to block interval pyloric and pyloric dilator I_A; effects on dopamine receptors (DARs) expressed in a heterologous expression system; effects on parental cell lines. Based on these criteria, we chose the best two drugs to examine in detail (flupenthixol and metoclopramide). We have not excluded the possibility that other drugs listed here are effective antagonists for lobster DARs.

plethora of targets in a single cell (Harris-Warrick et al. 1998; Nicola et al. 2000; Surmeier et al. 2007). Whereas the effects of DA on pyloric neurons and network output are well studied, little is known about how the signal is transduced. Here, for the first time, we defined the DA signal transduction cascade operating in an identified pyloric neuron. We found that LP exclusively expressed D1Rs perisynaptically but did not express D2Rs. DA modulation of LP I_A could be pharmacologically blocked by D1R but not D2R antagonists. Further, we demonstrated that LP D1Rs modulated I_A by coupling with the canonical signaling pathway that has been described for D1Rs in all species examined to date: Gs-AC-cAMP-PKA.

Differential effects of DA on LP and PD neurons are due to differences in receptor expression

It was previously shown that DA has opposing effects on two identified cell types of the pyloric motor circuit, LP and PD (Flamm and Harris-Warrick 1986a,b; Harris-Warrick et al. 1995a,b; Johnson et al. 2003a; Kloppe 1999, 2000; Peck et al. 2006). DA increases excitability and phase advances LP by increasing calcium currents ($I_{Ca}$) and a hyperpolarization activated inward current ($I_A$), while decreasing $I_A$. DA inhibits PD firing and phase delays neuronal activity by decreasing $I_{Ca}$ and increasing $I_A$. DA has no effect on PD $I_A$. Here we demonstrated that the cell specific effects of DA were due to differences in the DA transduction cascade in each cell type. In particular, LP expresses D1Rs and PD expresses D2Rs.

DAR expression was consistent at the protein level for both cell types. Every LP examined expressed somatodendritic D1Pan and D1Pan receptors, but not D2Pan receptors. Every PD examined expressed D2Rs, but not D1Rs (Oginsky et al. 2010). However, protein levels were not quantified, and receptor number for a given cell type may have varied across preparations. Surface receptors in both cell types appeared to be concentrated in synaptic varicosities within the somatodendritic compartment. These varicosities can represent pre- and/or postsynaptic structures (Oginsky et al. 2010). It is not clear if LP D1Rs are restricted to a subset of synapses as is the case for PD D2Rs (Oginsky et al. 2010).

**TABLE 1. List of drugs tested to screen DAR antagonists**

<table>
<thead>
<tr>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-)-Butaclamol</td>
</tr>
<tr>
<td>Clozapine</td>
</tr>
<tr>
<td>Sulpiride</td>
</tr>
<tr>
<td>Haloperidol</td>
</tr>
<tr>
<td>Spiperone HCl</td>
</tr>
<tr>
<td>Methiothepin mesylate</td>
</tr>
<tr>
<td>Metoclopramide</td>
</tr>
<tr>
<td>Cyproheptadine HCl</td>
</tr>
<tr>
<td>N-R(+)-SCH 23390</td>
</tr>
<tr>
<td>Chlorpromazine</td>
</tr>
<tr>
<td>(+)-Butaclamol</td>
</tr>
<tr>
<td>Domperidone</td>
</tr>
<tr>
<td>Etioctolide</td>
</tr>
<tr>
<td>Fluphenazine 2HCl</td>
</tr>
<tr>
<td>Flupenthixol</td>
</tr>
</tbody>
</table>

Three criteria were used to select an antagonist: ability to block interval pyloric and pyloric dilator I_A; effects on dopamine receptors (DARs) expressed in a heterologous expression system; effects on parental cell lines. Based on these criteria, we chose the best two drugs to examine in detail (flupenthixol and metoclopramide). We have not excluded the possibility that other drugs listed here are effective antagonists for lobster DARs.

**DI transduction cascades operate in LP neurons**

We showed that DA modulates LP $I_A$ by acting on $D_{1\text{Pan}}$ and/or $D_{1\text{Pan}}$ receptors that couple with a Gs-AC-cAMP-PKA pathway. Interestingly, there is no consensus cAMP-dependent phosphorylation site on shal channels (Baro et al. 1996). Shal channels may contain atypical PKA phosphorylation sites (Shi et al. 2007). Alternatively PKA may not act directly on the pore-forming subunit of the A-channel (i.e., shal subunits) but rather target an auxiliary subunit such as KChip (An et al. 2000) or a downstream enzyme (e.g., phosphatase) that then modifies shal subunits. The fact that DA shifted LP $I_A$ voltage dependencies to more positive potentials through D1R induced increases in cAMP may suggest that DA shifts PD $I_A$ voltage dependencies to more negative potentials via a D2-Gi/o coupled cascade that decreases cAMP and PKA activity. Indeed this is the case in D2R expressing striatal medium spiny neurons (Perez et al. 2006). However, DA may not act simply by reciprocally altering cAMP levels in LP and PD as DARs can act through noncanonical cascades: D2Rs can signal through PLCβ (Clark and Baro 2007; Hernandez-Lopez et al. 2000) and D1Rs can couple with Gq (Clark et al. 2008).

LP D1Rs increase cAMP levels. Interestingly, the literature suggests that cAMP signals can have different spatial attributes. In some cases, the cAMP signal is highly restricted to within one micron of the receptor (Zaccolo and Pozzan 2002), whereas in other cases, the signal can show varying degrees of global spread (Nikolaev et al. 2006; Rich et al. 2001). The type of signal generated does not depend on cell type but on the receptor signaling network (Nikolaev et al. 2006). Global cAMP signals are significantly different from local signals: Global signals are small and sustained, whereas local signals are large and transient (Rich et al. 2001). These distinct types of signals will produce different effects. For example, a global signal may only raise PKA activity slightly causing a small shift in the phosphorylation state of constitutively regulated proteins. On the other hand, a local signal may cause a large change in PKA activity that initiates new cascades by phosphorylating low affinity substrates. Indeed phosphorylation of the low affinity substrate, phosphodiesterase, which degrades cAMP to AMP, may underpin the transient versus sustained nature of the local versus global signal.

In pyloric neurons, surface DARs appeared to be concentrated on synaptic varicosities, which are, themselves, concentrated on the terminals of fine neurites. On the other hand, surface shal channels are localized throughout the somatodendritic compartment including the plasmalemma surrounding the soma and large diameter neurites (Baro et al. 2000). Given the spatial vagary of cAMP signals, and the significantly different character of local and global cAMP signals, this difference in protein distributions raises a very important question: are all shal channels modulated equally? Our current understanding of signal transduction suggests that most likely, they are not. However, the extent to which channels are differentially modulated in each compartment is an important matter for future studies.
Divergent and convergent modulatory systems

Both divergent and convergent modulatory systems exist in the STG. Monoaminergic systems appear to be divergent in three respects. First, a given monoamine can target multiple currents within a cell. For example, DA can alter $I_{A}$, $I_{Ca}$, and $I_{h}$ in the LP neuron (Harris-Warrick et al. 1995b; Johnson et al. 2003a). Second, a given monoamine can have diverse effects across cell types. For example, DA can increase $I_{A}$ in the PD neuron, decrease it in the LP, anterior burster (AB), inferior cardiac (IC), and pyloric constrictr (PY) neurons, and have no effect on the ventricular dilator (VD) $I_{A}$ although the synaptically isolated VD neuron responds to DA and so presumably has DARs (Flamm and Harris-Warrick 1986a,b; Harris-Warrick et al. 1995a,b; Kloppenburg et al. 1999; Peck et al. 2001). Third, each monoamine can alter a given current in different subsets of cells. For example, the effects of DA, serotonin (5-HT) and octopamine (OCT) on $I_{A}$ were studied in VD, AB, and IC neurons (Peck et al. 2001). All three neurons are known to respond to each modulator in the

FIG. 7. Dopamine receptor antagonists. cAMP was measured (pmol/mg protein) in cells expressing $D_{1a}$Pan, $D_{1b}$Pan, and $D_{2}$Pan receptors in the presence of 10$^{-5}$ M DA and increasing concentration of flupenthixol or metoclopramide. Data for a given experiment were normalized to the change in cAMP evoked by DA in the absence of antagonist. The change induced by DA + antagonist are expressed as a percent of the change induced by DA alone (indicated as 100%, - - -). Plots represent the average of 3 separate experiments, and a given point was the average of duplicates within each experiment.

Divergent and convergent modulatory systems

Both divergent and convergent modulatory systems exist in the STG. Monoaminergic systems appear to be divergent in three respects. First, a given monoamine can target multiple currents within a cell. For example, DA can alter $I_{A}$, $I_{Ca}$, and $I_{h}$ in the LP neuron (Harris-Warrick et al. 1995b; Johnson et al. 2003a). Second, a given monoamine can have diverse effects across cell types. For example, DA can increase $I_{A}$ in the PD neuron, decrease it in the LP, anterior burster (AB), inferior cardiac (IC), and pyloric constrictr (PY) neurons, and have no effect on the ventricular dilator (VD) $I_{A}$ although the synaptically isolated VD neuron responds to DA and so presumably has DARs (Flamm and Harris-Warrick 1986a,b; Harris-Warrick et al. 1995a,b; Kloppenburg et al. 1999; Peck et al. 2001). Third, each monoamine can alter a given current in different subsets of cells. For example, the effects of DA, serotonin (5-HT) and octopamine (OCT) on $I_{A}$ were studied in VD, AB, and IC neurons (Peck et al. 2001). All three neurons are known to respond to each modulator in the

FIG. 8. Flupenthixol but not metoclopramide blocked DA effects on LP $I_{A}$. The STG was sequentially exposed to the following treatments: a 10 min, 10$^{-5}$ M DA application, a 30 min wash, a 5 min, 10$^{-5}$ M antagonist application, and a 10 min antagonist + DA application. Data for a given experiment were normalized to the change in cAMP evoked by DA in the absence of antagonist. The change induced by DA + antagonist are expressed as a percent of the change induced by DA alone (indicated as 100%, - - -). Plots represent the average of 3 separate experiments, and a given point was the average of duplicates within each experiment.

$D_{1}$ RECEPTOR SIGNALING IN THE PYLORIC CIRCUIT

J Neurophysiol • VOL 104 • AUGUST 2010 • www.jn.org

by 10.220.32.247 on October 25, 2016 http://jn.physiology.org/ Downloaded from
intact ganglion and in synaptic isolation, i.e., each cell has receptors for each amine (Flamm and Harris-Warrick 1986a,b). Unlike DA, 5-HT alters \( I_N \) only in the IC neuron and OCT has no effect on \( I_N \) in AB, IC, or VD neurons. These findings for monoaminergic systems contrast with previously reported convergence in different neuromodulatory systems. Swensen and Marder (2000) demonstrated that five peptides [proctolin, crustacean cardioactive peptide (CCAP), Cancer borealis tachykinin related peptide Ia, red pigment-concentrating hormone, and TNRNFLRFamide] and acetylcholine acting at muscarinic receptors consistently altered the same voltage-gated inward current, \( I_{IN} \) (Zhao et al. 2010) in all cell types expressing receptors for the aforementioned modulators. However, not all STG neurons expressed all receptors, and the subset of cells that a given convergent modulator acted on varied (Swensen and Marder 2000, 2001). Thus whereas each convergent and divergent modulator can produce a distinct circuit output, they do so by different mechanisms. Convergent modulators will consistently target the same current but in different subsets of cells. On the other hand, each monoamine can differentially target multiple currents within the same cells.

In cases where a given cell expresses receptors for multiple convergent modulators, application of one modulator can occlude the other (Swensen and Marder 2000). This suggests that convergent modulators either signal globally or that the receptors are colocalized if signals are spatially restricted; otherwise, receptor induced changes in the current should be additive. The extent to which divergent monoaminergic modulators can occlude or potentiate one another is not clear. Future experiments using co-application of monoamines should yield valuable information on monoaminergic receptor localization and signaling.

The difference in divergent and convergent systems may be due, in part, to their molecular organization. Monoaminergic systems have multiple GPCRs in invertebrates: DA signals through at least three receptors, 5-HT acts on at least four receptors, and OCT/tyramine bind to eight receptors (Hauser et al. 2006). On the other hand, many of the aforementioned convergent modulators are known to act through a single GPCR in arthropods. In Drosophila, multiple studies have revealed that there is a single proctolin receptor (Egerod et al. 2003; Hauser et al. 2006; Johnson et al. 2003b). Similarly, there is one muscarinic receptor (Hauser et al. 2006) and one CCAP receptor (Hauser et al. 2006; Park et al. 2002) although there appear to be two CCAP receptors in the flour beetle (Arakane et al. 2008).

**Conclusion**

Our present work illuminates the molecular mechanisms underlying DA neuromodulation in an identified pyloric neuron, which is a prerequisite for understanding normal pyloric network function. We have shown that DA modulates \( LP \) \( I_N \) by acting on \( \mathrm{D}_1_{tn} \) and/or \( \mathrm{D}_2_{tn} \) receptors that couple with a Gs-AC-cAMP-PKA pathway. When considered in light of previous studies, these data not only help to explain the distinct physiological effects of DA on different pyloric cells but also indicate that DAR signal transduction is well conserved across species: DA acts on highly conserved D1Rs and D2Rs in both the crustacean STG and the mammalian striatum, which in turn activate well conserved canonical and noncanonical transduction cascades. The signaling networks activated by homologous DARs in mammals and crustaceans produce similar changes in their target ion channels. Because both the DARs and their ion channel targets can be accurately mapped onto three dimensional reconstructions of identified pyloric neurons, this system can be used for future, broadly applicable studies on the spatial aspects of signal transduction in geometrically complex cells.

**ACKNOWLEDGMENTS**

We thank K. J. Kent and T. Dever for technical assistance.

**GRANTS**

H. Zhang was supported by the Georgia State University Molecular Basis of Disease Fellowship. This work was funded by National Institute of Drug Abuse Grant DA024039 to D. J. Baro.

**DISCLOSURES**

No conflicts of interest, financial or otherwise, are declared by the author(s).

**REFERENCES**


